Table 1.
Baseline demographics and clinical lab results of the study cohort
| Overall Cohort (n = 36) |
Normal (n=16) |
Prediabetes or T2D (n=20) |
P-value | |
|---|---|---|---|---|
| Demographics | ||||
| Age, y | 56.1 ± 11.4 | 53.5 ± 11.7 | 58.2 ± 10.9 | 0.324 |
| Sex, n (M / F) | 17 / 19 | 6 / 10 | 11 / 9 | 0.478 |
| BMI, kg/m2 | 26.1 ± 3.39 | 25.4 ± 2.95 | 26.6 ± 3.72 | 0.427 |
| Ethnicity, n (Caucasian / Asian) | ||||
| 26 / 9 | 14 / 2 | 12 / 7 | 0.135 | |
| Medication Statin Use, n (Yes / No) | ||||
| 2 / 34 | 1 / 15 | 1 / 19 | 1.000 | |
| Smoking, n (Yes / No) | ||||
| 2 / 25 | 1 / 10 | 1 / 13 | 1.000 | |
| Season at Study Entry, n (Spring / Summer / Fall / Winter) | ||||
| 4 / 13 / 9 / 9 | 3 / 3 / 4 / 6 | 1 / 10 / 5 / 3 | 0.128 | |
| Exercise, min | 159 ± 114 | 204 ± 79.3 | 133 ± 126 | 0.0988 |
| Systolic Blood Pressure, mmHg | 116 ± 9.72 | 113 ± 8.97 | 119 ± 9.78 | 0.0946 |
| Diastolic Blood Pressure, mmHg | 72.5 ± 7.88 | 70.4 ± 7.27 | 74.1 ± 8.14 | 0.147 |
| Clinical Labs | ||||
| HbA1c, % | 5.64 ± 0.376 | 5.31 ± 0.224 | 5.90 ± 0.231 | 3.25e-07* |
| Fasting Plasma Glucose, mg/dL | 97.9 ± 12.9 | 90.6 ± 10.6 | 104 ± 11.7 | 0.00161* |
| Triglyceride,mg/dL | 93.2 ± 41.0 | 76.1 ± 33.4 | 107 ± 42.1 | 0.0142* |
| Total Cholesterol, mg/dL | 188 ± 35.8 | 182 ± 27.1 | 193 ± 41.5 | 0.464 |
| HDL, mg/dL | 61.5 ± 19.5 | 62.8 ± 12.9 | 60.4 ± 23.8 | 0.171 |
| LDL, mg/dL | 108 ± 28.7 | 104 ± 27.1 | 111 ± 30.1 | 0.265 |
| Non-HDL, mg/dL | 126 ± 34.0 | 119 ± 31.5 | 132 ± 35.4 | 0.143 |
| Fasting Insulin, mmol/L | 9.54 ± 6.93 | 6.59 ± 3.57 | 12.0 ± 8.10 | 0.00930* |
| Creatinine, mg/dL | 116 ± 70.6 | 121 ± 80.2 | 112 ± 63.3 | 0.921 |
| hs-CRP, mg/L | 1.19 ± 1.62 | 0.881 ± 0.854 | 1.44 ± 2.02 | 0.482 |
| ALT/SGPT, U/L | 27.3 ± 11.6 | 26.4 ± 9.95 | 28.1 ± 12.9 | 1.000 |
Continuous variables are reported as mean ± standard deviation, and categorical variables as count. Asterisk in the P-value column indicates statistical significance (P < 0.05) between normoglycemia and prediabetes/T2D groups.